Aortic valve stenosis (AS) is the most common valvular disease pathology in developed countries affecting over 5% of the population over the age of 75 [1] . Age is also the most significant risk factor in the development of aortic stenosis. As the global population ages [2], AS rates will continue to increase around the world. Some of the challenges that have surfaced in AS management are appropriate diagnosis of stenosis severity and timing of intervention. Patients who develop severe AS are monitored closely for the development of symptoms or the development of left ventricle (LV) function decline. International guidelines [3, 4] currently recommend intervention for severe AS once symptoms develop or when there is a decline in LV ejection fraction (LVEF). As the LV faces an increasing load from the fixed valve obstruction, it is critical that a decline in LV systolic function is not missed. Once missed, the risk of intervention for severe AS rises sharply.
Article p. 613
Aortic valve stenosis (AS) is the most common valvular disease pathology in developed countries affecting over 5% of the population over the age of 75 [1] . Age is also the most significant risk factor in the development of aortic stenosis. As the global population ages [2] , AS rates will continue to increase around the world. Some of the challenges that have surfaced in AS management are appropriate diagnosis of stenosis severity and timing of intervention. Patients who develop severe AS are monitored closely for the development of symptoms or the development of left ventricle (LV) function decline. International guidelines [3, 4] currently recommend intervention for severe AS once symptoms develop or when there is a decline in LV ejection fraction (LVEF). As the LV faces an increasing load from the fixed valve obstruction, it is critical that a decline in LV systolic function is not missed. Once missed, the risk of intervention for severe AS rises sharply.
In the present study, Hita et al. [5] demonstrate the use of LV diastolic function and increase in LV end-diastolic pressure (LVEDP) as markers of LV systolic function decline in patients with symptomatic AS. Twenty-six symptomatic patients with severe AS were evaluated prior to cardiovascular surgery with echocardiography and invasive catheterization. Patients with normal LVEDP (less than 15 mm Hg) were compared to patients with elevated LVEDP (over 15 mm Hg). Patients with elevated LVEDP were further subdivided into without coronary artery disease (CAD) or with CAD. Their data show that patients with increased LVEDP also had LV stiffness, measured as a ratio of LV pressure to LV end diastolic volume, and lower systolic longitudinal strain. They also showed that these hemodynamic changes were associated with histologic changes including a higher myocyte cross sectional and collagen volume. These findings suggest that severe AS with compensated LV function, defined by normal LVEDP, is hemodynamically and structurally different from decompensated severe AS.
This work has limitations including the small patient sample size. The study had 26 patients with 7 patients in two groups and 12 in the third group. Further, there were significant differences in the aortic valve gradient between the groups, which may independently account for the differences observed in LVEDP and LV stiffness or diastolic function.
This paper supports the concept that using LVEF to monitor LV systolic function may be too blunt a tool to guide the timing of intervention for severe AS. This study's findings are in keeping with the work of other researchers who have proposed the use of 2-dimensional (2D) longitudinal LV strain [6, 7] as a marker of future systolic dysfunction, in patients with severe AS, when LVEF is still preserved. Early identification of declining LV function is an important concern that is necessary in many areas of current medical care. These findings may be generalized to the monitoring of LV function in a wide range of conditions such as other valvular heart disease, like mitral regurgitation, side effects of chemotherapeutic agents, and degenerative cardiomyopathies.
This work raises the interesting question of whether we need to shift our focus to earlier diagnosis of impending LV dysfunction, instead of waiting for LV dysfunction to occur, prior to inter-
